196 related articles for article (PubMed ID: 26206333)
1. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
[TBL] [Abstract][Full Text] [Related]
3. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
[TBL] [Abstract][Full Text] [Related]
4. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J
Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y
BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS
Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828
[TBL] [Abstract][Full Text] [Related]
8. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS
ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252
[TBL] [Abstract][Full Text] [Related]
9. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
Ford CE; Lau SK; Zhu CQ; Andersson T; Tsao MS; Vogel WF
Br J Cancer; 2007 Mar; 96(5):808-14. PubMed ID: 17299390
[TBL] [Abstract][Full Text] [Related]
10. A new target for therapy in squamous cell carcinoma of the lung.
Ohashi K; Pao W
Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
[TBL] [Abstract][Full Text] [Related]
11. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH
Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953
[TBL] [Abstract][Full Text] [Related]
13. The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
López-Plana A; Fernández-Nogueira P; Muñoz-Guardiola P; Solé-Sánchez S; Megías-Roda E; Pérez-Montoyo H; Jauregui P; Yeste-Velasco M; Gómez-Ferreria M; Erazo T; Ametller E; Recalde-Percaz L; Moragas-Garcia N; Noguera-Castells A; Mancino M; Morán T; Nadal E; Alfón J; Domènech C; Gascon P; Lizcano JM; Fuster G; Bragado P
Int J Cancer; 2020 Aug; 147(4):1163-1179. PubMed ID: 31943158
[TBL] [Abstract][Full Text] [Related]
14. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
15. Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS; Huang PH
J Thorac Oncol; 2014 Jun; 9(6):900-4. PubMed ID: 24828669
[TBL] [Abstract][Full Text] [Related]
16. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
17. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
18. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G
Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362
[TBL] [Abstract][Full Text] [Related]
19. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
Chen XX; Zhou CC
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
[No Abstract] [Full Text] [Related]
20. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma.
Park JW; Lee YS; Kim JS; Lee SK; Kim BH; Lee JA; Lee NO; Kim SH; Hong EK
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1973-83. PubMed ID: 25842034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]